Shares of 23andMe sank Thursday, a day after the company reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price. 23andMe reported revenue ...

Regeneron Pharmaceuticals announced on Monday that it will acquire "substantially all" of genetic testing company 23andMe's assets. The pharmaceutical company said it won the court-supervised auction ...

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling ...

PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- 23andMe , a leading consumer genetics and research organization and nonprofit affiliate ...

23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs. Bay Area-based 23andMe ...

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

23andMe offers reports, among which are those based on statistical models known as polygenic scores (PRS). The PRS reports are developed by 23andMe scientists and clinical experts using the company’s ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth provider ...

23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 ...

23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs. The Sunnyvale, Calif.-based ...